Ocugen, Inc. · NASDAQ:OCGN
Ocugen — FY2022 Earnings Presentation
13 slides from Ocugen's earnings presentation, Feb 28, 2023
Slide 1: Q4 & Full Year 2022 Business Update
Q4 & Full Year 2022 Business Update February 28, 2023 NASDAQ:OCGN
Slide 2: Forward-Looking Statements
2 This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “antici
Slide 3: Biologics Accomplishments – 2022 & YTD
3 Vaccines COVAXINTM Completed enrollment in Phase 2/3 clinical trial OCU500 Series Developing an inhaled vaccine platform for the prevention of COVID-19 & flu Gene Therapies OCU400 Completed retinitis pigmentosa patient enrollment Completed dose- escalation of the Phase 1/2 clinical trial
Slide 4: FDA granted expanded Orphan Drug Designations for RP and LCA mutations
FDA granted expanded Orphan Drug Designations for all retinitis pigmentosa (RP) and Leber congenital amaurosis (LCA) mutations Despite its prevalence, RP and LCA patients have limited treatment options • US: RP & LCA affect 110K and 15K people, respectively • Worldwide: conditions affect approximate
Slide 5: OCU200: Submitted an IND with the US FDA to Initiate a Phase 1 Clinical Trial
5 OCU200: Submitted an IND with the US FDA Yesterday to Initiate a Phase 1 Clinical Trial Targeting Diabetic Macular Edema (DME) OCU200 is our novel biologics candidate for sight-threatening conditions • A recombinant fusion protein of tumstatinand transferrin • Potential to address diabetic macular
Slide 6: NeoCart: US FDA Agreed to Proposed Control and Overall Design for Phase 3 Trial
6 NeoCart®: US FDA Agreed to Proposed Control and Overall Design for Phase 3 Trial to Evaluate Safety and Efficacy Compared to Chondroplasty Standard of Care *The Journal of Bone & Joint Surgery: June 1, 2011 - Volume 93 - Issue 11 - p 994-1000 **https://www.biospace.com/article/cell-therapy-market-
Slide 7: OCU500 Series: Next-Generation Inhaled Vaccine Candidates
7 OCU500 Series: Next-Generation Vaccine Candidates Using Inhalation Technology to Potentially Overcome Durability and Transmission Challenges OCU500 A bivalent COVID-19 vaccine OCU510 A seasonal quadrivalent flu vaccine OCU520 A combination quadrivalent flu and bivalent COVID19 vaccine COVID-19 and
Slide 8: COVAXIN (BBV152): Final Data and Analysis Expected Mid-Year 2023
8 COVAXIN™(BBV152): Final Data and Analysis Expected Mid-Year 2023 for Our Injectable COVID-19 Vaccine Enrollment completed for Phase 2/3 immuno-bridging and broadening clinical trial in December 2022 Topline data highlights, reported in January 2023, include the following: • Safety: well-tolerated
Slide 9: 2023: Several Significant Milestones Expected
9 OCU500 series NeoCart® OCU400 OCU410/410ST OCU200 Q1 Q2 Q3 Q4 IND filing to initiate clinical trials cGMP facility completion Initiation of Phase 3 clinical trial IND submissions: Phase 1/2 clinical trials in dry AMD & Stargardt disease Dosing of patients in Phase 1 clinical trial Preliminary data
Slide 10: Financial Update
Financial Update ocugen.
Slide 11: Statement of Operations and Balance Sheet Data
Statement of Operations Three months ended December 31, Year ended December 31, 2022 2021 2022 2021 Research and development expense $17.2 $7.1 $49.8 $35.1 General and administrative expense 6.9 7.5 35.1 22.9 Other income (expense), net 2.2 — 3.5 (0.4) Net loss $(21.9) $(14.6) $(81.4) $(58.4) Net lo
Slide 12: Questions & Answers
Questions & Answers ocugen.
Slide 13: Thank you!
February 2023 NASDAQ:OCGN Thankyou!